Search results
Results from the WOW.Com Content Network
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CRISPR Therapeutics wasn’t one of them. The 10 stocks that ...
3. The balance sheet is rock solid. The last reason to buy this stock today is that its balance sheet is looking as good as it gets in biotech. At the end of the first quarter, it had around $2.1 ...
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise ...
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland.It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases.
At the moment, CRISPR Therapeutics (NASDAQ: CRSP) is in a special period that most biotechs never survive to reach. Small groups of patients are now being treated with its first medicine to reach ...
Stock name Symbol Country of origin Nabors Industries: NBR: United States: NACCO Industries: NC: United States: Nam Tai Property Inc. NTP: Hong Kong: National Bank Holdings Corporation NBHC: United States: National Bank of Greece: NBG: Greece: National Fuel Gas: NFG: United States: National Grid plc: NGG: United Kingdom: National Health ...
It won't be able to be profitable without hitting its targets for both of these figures.